Published
July 29, 2026
A proposed class action accuses Lemme Inc. — the supplement brand co-founded by Kourtney Kardashian Barker — of selling its $90-a-month GLP-1 Daily capsules as a natural stand-in for Ozempic without clinical proof that they curb appetite or take off weight. If you bought the capsules, the case is worth watching, but it was filed this month and there is nothing to claim.
Allegations Only · No Settlement Yet
This article describes a class action complaint. The statements below are unproven allegations. Lemme Inc. has not been found liable, there is no certified class, and there is nothing to claim at this time. This page is informational and is not legal advice.
What Is This About?
A proposed class action filed in the U.S. District Court for the Central District of California alleges that Lemme Inc. sold its "Lemme GLP-1 Daily" capsules by promising something the company could not back up: that raising your body's own GLP-1 with a plant-extract pill would suppress appetite and produce weight loss the way prescription drugs like Ozempic and Wegovy do. The case is captioned Tiberia v. Lemme Inc., No. 2:26-cv-07581, and was filed on July 13, 2026. Lemme has not been found liable, and the allegations remain unproven.The named plaintiff, a California resident, says she saw an Instagram advertisement in about October 2024, was routed to the company's website, and bought the capsules believing they would deliver appetite control and weight loss comparable to a prescription GLP-1 drug. She alleges she took two capsules a day as directed for more than three months. Her claimed injury is economic rather than physical: she says she paid a price premium for benefits the product could not deliver, and would not have bought it — or would have paid less — had she known.
Status
Complaint Filed · July 13, 2026
Proposed class action · Tiberia v. Lemme Inc. · No. 2:26-cv-07581 (C.D. Cal.)
Allegation
GLP-1 Daily capsules sold as a natural equivalent to prescription GLP-1 drugs without clinical support
Complaint alleges the cited studies showed a ~17% GLP-1 increase but no change in weight, BMI, fat mass, or calories consumed
Who's Covered (Proposed)
U.S. purchasers, plus a California subclass
No class has been certified · the definitions can still change
Can I Claim?
No — nothing to claim yet
No settlement, no fund, no claim form, no deadline
The Product and What It Cost
Lemme launched GLP-1 Daily on or about September 16, 2024, initially selling it through its own website. According to the complaint, a one-month supply runs $90, and a six-month subscription runs $378, with instructions to take two capsules a day with food and marketing that says the "best results" require consistent daily use for at least three to six months.The formula is a blend of three plant extracts — Eriomin lemon fruit extract, Supresa saffron extract, and Morosil red orange fruit extract. Trade press reporting indicates the product has since been renamed Lemme Reset with the same formulation and has expanded beyond the brand's own site into major retailers. If you are trying to work out whether you bought the product at issue, the ingredient list is a more reliable guide than the name on the bottle.
The "Natural Ozempic" Theory
The heart of the case is a comparison. Prescription GLP-1 agonists — semaglutide in Ozempic and Wegovy, tirzepatide in Mounjaro and Zepbound — are widely understood by consumers to produce real appetite suppression and weight loss, and they are expensive enough that many people cannot get them covered. The complaint alleges Lemme positioned its capsules to capture that demand, calling GLP-1 the "un-hunger" hormone, describing the product as a "groundbreaking natural GLP-1 solution with no known side effects," and telling shoppers it would "safely increase your GLP-1 levels."The complaint also alleges a second move: that Lemme's advertising leaned on the side effects associated with prescription GLP-1 drugs to frame those medications as risky while implicitly presenting its own capsules as delivering the same results more safely. The allegation is that this shifted consumer attention from whether the product works to whether it is gentler — and that reasonable consumers took the overall message to be that the supplement is a natural equivalent to the drugs.
Nothing in the complaint alleges the capsules are dangerous. The claimed harm is that people paid a premium for an effect the plaintiff says was never substantiated.
Why the Plaintiff Says a 17% GLP-1 Bump Does Nothing
The substantiation fight turns on a specific number. The complaint alleges Lemme pointed to clinical studies showing that the trademarked lemon extract, Eriomin, raises naturally occurring GLP-1 by about 17 percent — and then argues that figure cannot support a weight-loss claim, for several reasons.First, according to the complaint, natural GLP-1 has a half-life of only one to two minutes before enzymes break it down, which is precisely why pharmaceutical companies engineered modified versions that resist that breakdown; semaglutide, it alleges, lasts about seven days per dose. Second, the complaint alleges that eating a meal raises blood GLP-1 from roughly 5–10 pmol/L to about 50 pmol/L on its own — a 400 to 900 percent swing — so a 17 percent increase is small next to what a sandwich does. Third, it alleges a 1 mg weekly dose of semaglutide produces blood concentrations orders of magnitude higher than resting natural GLP-1.
Most directly, the complaint alleges the studies Lemme relied on reported no weight effect at all. It quotes the 2019 study as finding that supplementation with Eriomin at 200, 400, and 800 mg/day "had no effect on body weight, BMI, lean mass, fat mass, fat percentage, and hip waist ratio," and the 2022 study as reporting no effect on blood pressure, body weight, BMI, lean mass, fat mass, or hip-to-waist ratio. It further alleges the calories participants consumed did not change during the study. The complaint separately alleges the three extracts were never clinically tested together as a single combined product.
These are the plaintiff's characterizations of the underlying research, presented in a complaint. Lemme has not yet responded in court, and a judge has not evaluated any of it.
Is Kourtney Kardashian Barker Being Sued?
No. The only defendant named in this complaint is Lemme Inc., the company — described in the filing as a Delaware corporation headquartered in New York. The complaint mentions Kourtney Kardashian Barker and Simon Huck as the brand's founders by way of background, but neither is a defendant and no claims are asserted against either of them personally.This distinction matters for readers trying to follow the case. Coverage of celebrity-backed brands often blurs the company and the celebrity; here, the legal exposure alleged in this filing sits with the corporation.
This Is Not the First Challenge to These Claims
Legal and supplement trade press reported two earlier proposed class actions over the same product in 2025, both captioned Robins v. Lemme Inc. — one filed in California Superior Court on February 19, 2025 and one in the U.S. District Court for the Southern District of New York on March 9, 2025. Those cases raised the same core theory: that marketing the capsules as a natural route to GLP-1-driven weight loss outran the science.We were not able to confirm from a primary court record how those two earlier cases ended, and published accounts of their disposition are not consistent, so we are not characterizing the outcome here. What can be said is that the theory in the new California case is not novel, and that the product's GLP-1 marketing has drawn repeated legal attention.
What the Lawsuit Seeks
The complaint brings three California claims: the False Advertising Law (Cal. Bus. & Prof. Code §§ 17500 et seq.), the Consumers Legal Remedies Act (Cal. Civ. Code §§ 1750–1785), and the Unfair Competition Law (Cal. Bus. & Prof. Code §§ 17200 et seq.). The FAL count is pleaded on behalf of a nationwide class or, alternatively, a California subclass; the CLRA and UCL counts are pleaded for the California subclass. The complaint states that the required CLRA pre-suit notice was received by Lemme on April 6, 2026.It asks the court to:
• Certify the proposed classes and appoint the plaintiff and her counsel to represent them.
• Award restitution of the price premium — the difference between what buyers paid and what they would have paid absent the challenged claims.
• Award actual, statutory, and punitive damages, plus pre- and post-judgment interest.
• Enter public injunctive relief stopping the challenged advertising going forward.
• Award attorneys' fees, costs, and expert witness fees.
The plaintiff is represented by the Law Offices of Robert Mackey and Robert Peirce & Associates, P.C., and demands a jury trial. All of the above are requests tied to unproven allegations; no money has been awarded and no court has found any statement by Lemme to be false.
Who Could Be Affected?
The complaint proposes a nationwide class of everyone in the United States who bought the product within the limitations period, and a California subclass of California residents who bought it within the statute of limitations. Company insiders, affiliates, counsel, and the assigned judge's household are excluded.No class has been certified, and the plaintiff expressly reserves the right to redefine the classes as the case develops — so the eventual scope, if the case gets that far, could be narrower or broader. If you bought the capsules, holding onto order confirmations, subscription records, or credit card statements is a reasonable precaution. There is nothing to file right now.
Beware of Lemme Refund Scams
Important: when a class action hits a celebrity-linked brand, scammers follow with fake "refund" texts, emails, and DMs asking you to click a link, confirm card details, or pay a small processing fee. There is no Lemme claim form and no settlement. A real claims process — if one ever exists — would be run by a court-appointed administrator, would be free, and would never ask for banking passwords, gift cards, or up-front payments.What Happens Next?
The case is at its earliest stage. Lemme will have an opportunity to respond, most likely with an answer or a motion to dismiss, and substantiation cases like this one frequently draw early challenges to standing, to the nationwide reach of California statutes, and to whether the advertising can be read the way the complaint reads it. If the case survives, the plaintiff would then have to persuade the court to certify a class.Any of that can take months or years, and the case could be narrowed, amended, settled, or dismissed along the way. OpenClassActions.com will update this page if a motion to dismiss is decided, a class is certified, or a settlement with an actual claim form is announced.
Questions
What does the Lemme GLP-1 Daily lawsuit allege?
The complaint alleges that Lemme Inc. marketed its GLP-1 Daily capsules as a natural, side-effect-free way to raise the body's own GLP-1 and get appetite suppression and weight loss comparable to prescription drugs such as Ozempic and Wegovy, without competent scientific substantiation for those specific claims. It alleges the studies Lemme relied on found a roughly 17 percent rise in GLP-1 but no change in body weight, BMI, fat mass, waist-to-hip ratio, or calories consumed. Lemme has not been found liable and the allegations are unproven.
Is Kourtney Kardashian Barker a defendant in the Lemme lawsuit?
No. The only named defendant is Lemme Inc., the company. The complaint identifies Kourtney Kardashian Barker and Simon Huck as the brand's founders as background, but neither is sued, and no claims are asserted against either of them individually.
Is Lemme GLP-1 Daily the same product as Lemme Reset?
According to trade press reporting, the product launched as Lemme GLP-1 Daily and was later renamed Lemme Reset with the same formulation — a blend of Eriomin lemon fruit extract, Supresa saffron extract, and Morosil red orange fruit extract. The complaint's own citation to the Lemme website points to a page carrying the Reset name at the same product URL. Anyone checking whether they bought the product should look at the ingredients rather than the name on the bottle.
Is there a Lemme settlement or money to claim right now?
No. This is a newly filed complaint. There is no settlement, no settlement fund, no certified class, and no claim form. Anyone asking you to pay a fee to file a Lemme claim today is running a scam. The complaint seeks restitution, damages, and injunctive relief under California's False Advertising Law, Consumer Legal Remedies Act, and Unfair Competition Law.
Why does the lawsuit say a 17 percent GLP-1 increase is not enough?
The complaint alleges that natural GLP-1 breaks down in one to two minutes and that simply eating a meal raises blood GLP-1 by roughly 400 to 900 percent on its own, so a 17 percent bump would not meaningfully change appetite. It contrasts this with semaglutide, which it alleges reaches vastly higher concentrations and lasts about seven days per dose. These are the plaintiff's allegations and characterizations of the underlying studies; they have not been tested in court.
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
Official Class Action Complaint
Sources
- Class Action Complaint, Tiberia v. Lemme Inc., No. 2:26-cv-07581, U.S. District Court, Central District of California (filed July 13, 2026) — embedded above
- Ribeiro C.B., Ramos F.M., Manthey J.A., Cesar T.B., "Effectiveness of Eriomin in managing hyperglycemia and reversal of prediabetes condition: A double-blind, randomized, controlled study," Phytotherapy Research (2019) — cited in the complaint
- Cesar T.B., Ramos F.M., Ribeiro C.B., "Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial," Journal of Medicinal Food (2022) — cited in the complaint
- PR Newswire — Lemme Innovates With Natural GLP-1 Supplement, Launching on September 16th (Sept. 12, 2024)
- Bloomberg Law — Kardashian Vitamin Brand Lemme Sued Over GLP-1 Supplement Claims
- National Law Review — Two Class Actions Target Supplement Promoted for Increasing GLP-1 (on the 2025 Robins filings)
- NutraIngredients — Lemme lawsuits challenge GLP-1 supplement claims (ingredient suppliers and study details)
For more class actions keep scrolling below.
Status
Complaint Filed — Allegations Unproven
Case Title
Tiberia v. Lemme Inc.
Case Number
2:26-cv-07581
Court
U.S. District Court, Central District of California
Date Filed
July 13, 2026
Product
Lemme GLP-1 Daily capsules
Later marketed as Lemme Reset · Eriomin lemon, Supresa saffron, and Morosil red orange extracts
Claims
California FAL, CLRA, and UCL
